Thrombosis and Meningococcal Infection Rates in Pegcetacoplan Patients with Paroxysmal Nocturnal Hemoglobinuria in the Clinical Trial and Post-Marketing Settings (EHA) 2023 PNH
Incidence Rates of Healthcare Resource Utilization and Hemoglobin Levels during OPERA: a Real-World Study of Pegcetacoplan Treatment in US Adults with Paroxysmal Nocturnal Hemoglobinuria (EHA) 2023 PNH
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.
The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available fo rthe uses being investigated.
If you are a Healthcare Professional licensed to practice in the United States
If you are a Healthcare Professional licensed to practice in Canada
If you are a Healthcare Professional licensed to practice in Europe
If you are a Healthcare Professional licensed to practice in Australia